IMMX
Immix Biopharma, Inc. Health Care Pharmaceutical Preparations Russell 3000
$7.68Close
$406.7MMarket cap
$3.03 – $14.4752-week range
Nov 6, 2026Next report
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 47% below its 52-week high
- Distribution down-day volume 2.4× up-day volume over 50 sessions
- Results soon Nov 6, 2026, in 5 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
47%
1wk
down 5.8%
price change
1mo
down 26.2%
price change
12-month return
up 109%
market up 11% ·
its own up 96%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.3×
price / book
Earnings yield
down 9.6%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 55%
return on equity
Free cash margin
—
-$24.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.9%
$0.61 a day · 2×ATR $6.47
RS
77 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, over 25% off the high
Relative volume
0.9×
vs 50-day average
Up/down volume
0.42
50 sessions
Implied move
—
no option chain · report Nov 6, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 92.3% over the year, from 28m to 53m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last shock
Jul 20, 2026-14% in one session1.9× volumeon an SEC filing-13% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$453,852 | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$30.0M |
| Net income | -$1.1M | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
| Earnings per share | — | -$6.64 | -$0.59 | -$0.89 | -$0.76 | -$0.89 |
| Free cash flow | -$404,694 | -$1.6M | -$7.4M | -$11.4M | -$15.8M | -$24.7M |
| Cash | $391,086 | $17.6M | $13.4M | $17.5M | $17.7M | $93.9M |
| Shareholders' equity | -$4.7M | $18.0M | $13.2M | $16.4M | $13.3M | $93.8M |
| Shares outstanding | 3.38m | 13.23m | 13.89m | 19.92m | 27.54m | 52.95m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 25, 2026 | Annual ↗ | Dec 31, 2025 | 84d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 25, 2025 | Annual ↗ | Dec 31, 2024 | 84d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 29, 2024 | Annual ↗ | Dec 31, 2023 | 89d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 30, 2026 | Other events ↗ |
| Sep 29, 2026 | Regulation FD · Other events ↗ |
| Jul 20, 2026 | Other events ↗ |
| May 29, 2026 | Shareholder vote ↗ |
| May 21, 2026 | Other events ↗ |
| May 21, 2026 | Regulation FD · Other events ↗ |
| Mar 30, 2026 | Regulation FD · Other events ↗ |
| Mar 25, 2026 | Material agreement ↗ |
| Dec 8, 2025 | Material agreement ↗ |
| Dec 8, 2025 | Regulation FD · Other events ↗ |
| Nov 26, 2025 | Other events ↗ |
| Sep 8, 2025 | Material agreement · Unregistered share sale · Director or officer change ↗ |